active substance: chondroitin sulfate sodium;
1 capsule contains chondroitin sodium sulfate 500 mg;
excipients: the capsule contains talc; capsule shell – gelatin, indigotine, titanium dioxide.
Dosage form. Capsules.
Pharmacotherapeutic group. Not steroid anti-inflammatory and Antirheumatic agents.
ATC code M01A X25.
Secondary therapy in degenerative diseases of joints and spine (osteoarthritis, low back pain between the vertebral).
Allergic reactions in the anamnesis of any components of the drug.
Children up to age 15 years.
Method of application and doses.
Capsules swallow whole, washed down with 250 ml of water.
Adults and children over 15 years take 1 capsule (500mg) twice a day (total 1 g / day). The duration of treatment is 3-6 months.
Dermatological reactions: rarely – erythema, urticaria, dermatitis, maculopapular rash (with or without itching) and/or swelling.
From the digestive tract in rare cases – nausea, vomiting.
In case of overdose, the patient must immediately hospitalized.
Treatment is symptomatic.
Use during pregnancy or breast-feeding.
Since the study was conducted, the preparation is not recommended for pregnant women and women who breastfeed.
The drug is contraindicated in children under the age of 15 years.
Features of the application.
The preparation is not recommended for pregnant women and women who breastfeed.
The ability to influence the rate of reaction at management of motor transport or operating other mechanisms.
Interaction with other medicinal products and other forms of interaction.
The pharmacological properties.
Chondroitin sulfate – an important component of bones and cartilage of the joints, which helps to maintain the integrity of the cartilage matrix by:
increase in anabolic activity of chondrocytes (stimulation of the synthesis of proteoglycans);
the inhibition of the adverse effects of Il-1β on cartilage matrix;
to prevent excessive degradation of the extracellular matrix of cartilage (by inhibiting elastase in the tissues and by reducing the activity of metalloprotease such as tromelin and collagen Aza, in parallel with the increase in the activity of tissue inhibitor metalloprotease that blocks these enzymes).
Chondroitin sulfate also improves the homeostasis of the synovial environment of the joints by stimulating the synthesis of hyaluronic acid, thus maintaining the proper viscosity of synovial fluid. Through enzymatic and antivulnerability properties of chondroitin sulfate inhibits the development of inflammatory reactions.
After oral administration of chondroitin sulfate is absorbed in the gastrointestinal tract, the maximum concentration in plasma achieved within 4 hours.
The drug will be heard predominantly in the synovial fluid. It is excreted mainly with faeces.
Basic physical and chemical properties: opaque blue capsule which contains white or yellowish powder.
The expiration date. 3 years.
The storage conditions. Keep at temperature not exceeding 25 °C. Keep out of reach of children.
Packing. At 12 capsules in blister. For 5 blisters in a cardboard box.